Published in Science on March 10, 2016
CAR-T Cell Immunotherapy for Advanced Lung Cancer | NCT03330834
Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity. Science (2016) 1.52
Multi-organ Mapping of Cancer Risk. Cell (2016) 1.30
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell (2017) 0.94
Different promoter affinities account for specificity in MYC-dependent gene regulation. Elife (2016) 0.93
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade. Cancer Immunol Res (2016) 0.88
Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol (2017) 0.86
Innate immune signaling and regulation in cancer immunotherapy. Cell Res (2016) 0.86
Mouse models in oncoimmunology. Nat Rev Cancer (2016) 0.85
What does PD-L1 positive or negative mean? J Exp Med (2016) 0.79
MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer. Oncogene (2017) 0.79
Optogenetic Immunomodulation: Shedding Light on Antitumor Immunity. Trends Biotechnol (2016) 0.78
Emerging roles of p53 and other tumour-suppressor genes in immune regulation. Nat Rev Immunol (2016) 0.78
A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer. Nat Commun (2017) 0.78
Gene signature driving invasive mucinous adenocarcinoma of the lung. EMBO Mol Med (2017) 0.77
Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. Oncoimmunology (2017) 0.77
MGUS to myeloma: a mysterious gammopathy of underexplored significance. Blood (2016) 0.76
Tumour immunology: Another string to the MYC bow. Nat Rev Cancer (2016) 0.75
Strategies to Inhibit Myc and Their Clinical Applicability. Front Cell Dev Biol (2017) 0.75
MYC: Master Regulator of Immune Privilege. Trends Immunol (2017) 0.75
The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9. Nat Immunol (2016) 0.75
Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myeloma. J Transl Med (2016) 0.75
The MYCN Protein in Health and Disease. Genes (Basel) (2017) 0.75
Small molecule selectively suppresses MYC transcription in cancer cells. Proc Natl Acad Sci U S A (2017) 0.75
PBMC transcriptome profiles identifies potential candidate genes and functional networks controlling the innate and the adaptive immune response to PRRSV vaccine in Pietrain pig. PLoS One (2017) 0.75
MYC - a thorn in the side of cancer immunity. Cell Res (2016) 0.75
Comparative Analysis of Immune Checkpoint Molecules and Their Potential Role in the Transmissible Tasmanian Devil Facial Tumor Disease. Front Immunol (2017) 0.75
Modeling and Targeting MYC Genes in Childhood Brain Tumors. Genes (Basel) (2017) 0.75
BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1. Cell Rep (2017) 0.75
Inflammation, phagocytosis and cancer: another step in the CD47 act. J Thorac Dis (2017) 0.75
Cytoplasmic expression of C-MYC protein is associated with risk stratification of mantle cell lymphoma. PeerJ (2017) 0.75
Human Cancer Cells Signal Their Competitive Fitness Through MYC Activity. Sci Rep (2017) 0.75
Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies. Br J Cancer (2017) 0.75
Tri-methylation of H3K79 is decreased in TGF-β1-induced epithelial-to-mesenchymal transition in lung cancer. Clin Epigenetics (2017) 0.75
Pathological and Genetic Characterization of Bilateral Adrenomedullary Hyperplasia in a Patient with Germline MAX Mutation. Endocr Pathol (2016) 0.75
Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature (2017) 0.75
Mithramycin-loaded mPEG-PLGA nanoparticles exert potent antitumor efficacy against pancreatic carcinoma. Int J Nanomedicine (2017) 0.75
Inflammation and cancer: back to Virchow? Lancet (2001) 27.40
Selective inhibition of BET bromodomains. Nature (2010) 18.79
Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science (2002) 17.38
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Transcriptional amplification in tumor cells with elevated c-Myc. Cell (2012) 8.24
Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell (1999) 8.03
Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol (2006) 7.76
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol (2012) 7.26
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med (2006) 7.10
c-MYC: more than just a matter of life and death. Nat Rev Cancer (2002) 6.73
c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell (2012) 6.49
c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev (2006) 6.19
Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev (2001) 5.67
MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature (2004) 5.61
CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell (2009) 5.30
CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell (2009) 5.22
Control of cell growth by c-Myc in the absence of cell division. Curr Biol (1999) 3.90
Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet (2000) 3.67
c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med (2001) 3.51
Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci U S A (2007) 3.37
CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell (2010) 3.33
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity (2000) 3.07
Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. Blood (2007) 3.00
Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-myc. Mol Cell Biol (2006) 2.85
Primary antitumor immune response mediated by CD4+ T cells. Immunity (2005) 2.72
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell (2015) 2.52
New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. Curr Opin Immunol (2014) 2.47
Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis. Nature (2014) 2.38
Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles. Nature (2014) 2.33
Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res (2010) 2.25
Conditional gene expression in secretory tissues and skin of transgenic mice using the MMTV-LTR and the tetracycline responsive system. J Cell Biochem (1995) 1.93
Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proc Natl Acad Sci U S A (2006) 1.89
Classification of current anticancer immunotherapies. Oncotarget (2014) 1.55
Innate immune recognition of cancer. Annu Rev Immunol (2015) 1.52
CD8 T cell help for innate antitumor immunity. J Immunol (2007) 1.39
MYC through miR-17-92 suppresses specific target genes to maintain survival, autonomous proliferation, and a neoplastic state. Cancer Cell (2014) 1.36
Taming of the beast: shaping Myc-dependent amplification. Trends Cell Biol (2014) 1.19
Experimental mouse tumour models: what can be learnt about human cancer immunology? Nat Rev Immunol (2011) 1.17
Thrombospondin-1 signaling through CD47 inhibits self-renewal by regulating c-Myc and other stem cell transcription factors. Sci Rep (2013) 1.12
The role of MIZ-1 in MYC-dependent tumorigenesis. Cold Spring Harb Perspect Med (2013) 1.10
Reversible lymphomagenesis in conditionally c-MYC expressing mice. Int J Cancer (2004) 1.06
T cell stimulation via CD47: agonistic and antagonistic effects of CD47 monoclonal antibody 1/1A4. J Immunol (1997) 1.04
Anti-PD-1 therapy in melanoma. Semin Oncol (2015) 0.93
Role of CD47 in the induction of human naive T cell anergy. J Immunol (2001) 0.89
MYC: Master Regulator of Immune Privilege. Trends Immunol (2017) 0.75